Hepatic exposure of metformin in patients with non‐alcoholic fatty liver disease

Aims Metformin is first‐line treatment of type 2 diabetes mellitus and reduces cardiovascular events in patients with insulin resistance and type 2 diabetes. Target tissue for metformin action is thought to be the liver, where metformin distribution depends on facilitated transport by polyspecific t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2019-08, Vol.85 (8), p.1761-1770
Hauptverfasser:	Sundelin, Elias Immanuel Ordell, Gormsen, Lars Christian, Heebøll, Sara, Vendelbo, Mikkel Holm, Jakobsen, Steen, Munk, Ole Lajord, Feddersen, Søren, Brøsen, Kim, Hamilton‐Dutoit, Stephen Jacques, Pedersen, Steen Bønløkke, Grønbæk, Henning, Jessen, Niels
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Biopsy Carbon Radioisotopes Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - etiology Female Gene Expression Profiling Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacokinetics Liver - metabolism Liver - pathology Male metformin Metformin - administration & dosage Metformin - pharmacokinetics Middle Aged Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - diagnosis Non-alcoholic Fatty Liver Disease - metabolism Non-alcoholic Fatty Liver Disease - pathology non‐alcoholic fatty liver disease Organic Cation Transport Proteins - genetics Organic Cation Transport Proteins - metabolism organic cation transporters Original pharmacokinetics Positron Emission Tomography Computed Tomography Tissue Distribution
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!